Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours-Reference-Cited by-同舟云学术

Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours

Published:2020-11-19 Issue: Volume: Page:
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Bagrodia Aditya¹^ORCID,Savelyeva Anna¹,Lafin John T.¹,Speir Ryan W.²^ORCID,Chesnut Gregory T.³,Frazier Anne Lindsay⁴,Woldu Solomon L.¹,Margulis Vitaly¹⁵^ORCID,Murray Matthew J.⁶⁷^ORCID,Amatruda James F.⁸,Lotan Yair¹^ORCID

Affiliation:

1. Department of Urology; University of Texas Southwestern Medical Center; Dallas TX USA

2. Madigan Army Medical Center; Joint Base Lewis-McChord; Tacoma WA USA

3. Walter Reed National Military Medical Center; Bethesda MD USA

4. Dana-Farber/Boston Children’s Cancer and Blood Disorder Center; Boston MA USA

5. Department of Urology; I.M. Sechenov First Moscow State University; Moscow Russia

6. Department of Pathology; University of Cambridge; Cambridge UK

7. Department of Pediatric Hematology and Oncology; Cambridge University Hospitals NHS Foundation Trust; Cambridge UK

8. Departments of Pediatrics and Medicine; Keck School of Medicine; Cancer and Blood Disease Institute; Children's Hospital Los Angeles; University of Southern California; Los Angeles CA USA

Funder

St. Baldrick’s Consortium Award

Cancer Prevention and Research Institute of Texas

Malignant Germ Cell International Consortium

Dedman Family Scholarship in Clinical Care

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.15288/fullpdf

Reference27 articles.